Form 4: Aptevo Therapeutics CEO Exercises Restricted Stock Units
SEC Form 4 Filing
Marvin L. White, President and CEO of Aptevo Therapeutics Inc., converted restricted stock units into common stock on March 2nd and 3rd, 2024.
Summary
- Marvin L. White, the President and CEO of Aptevo Therapeutics Inc., executed transactions involving restricted stock units (RSUs).
- On March 2, 2024, White converted 12,917 RSUs into common stock.
- On March 3, 2024, White converted 9,584 RSUs into common stock.
- These transactions increased White's direct holdings of Aptevo Therapeutics common stock to 67,430 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives, ensuring transparency in insider trading activities.
- Similar filings are made by executives at comparable biotech companies like Amgen, Gilead Sciences, and Biogen, whenever they buy or sell company stock or exercise stock options.
Stakeholder Impact
- The conversion of RSUs into common stock may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 2022-06-07 | Reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. |
| 2023-03-03 | Reporting person was granted 38,750 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. |
| 2024-03-02 | 12,917 Restricted Stock Units converted to common stock. |
| 2024-03-03 | 9,584 Restricted Stock Units converted to common stock. |
| 2024-03-05 | Date of signature for the Form 4 filing. |
Keywords
Aptevo Therapeutics, Marvin L. White, Restricted Stock Units, RSUs, Common Stock, Form 4, SEC Filing, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.